|
|
NanoAlum |
|
Vaxjo ID |
179 |
|
Vaccine Adjuvant Name |
NanoAlum |
|
Adjuvant VO ID |
VO_0005475
|
|
Description |
A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
Mouse |
|
Components |
alhydrogel adjuvant |
|
Storage |
2-8C |
|
Preparation |
high-pressure microfluidization—to generate aluminum oxyhydroxide nanoparticles, hereupon referred to as nanoalum, using the clinically approved Alhydrogel adjuvant as the precursor |
|
Function |
innate immune activation |
| References |
(Soza, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=71]
Orr et al., 2019: Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB. Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. NPJ vaccines. 2019; 4; 1. [PubMed: 30622742].
|
|
